Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

MPM leads $12mm Series E round for Elixir Pharmaceuticals

Executive Summary

Elixir Pharmaceuticals (metabolic diseases) has raised $12mm through its Series E venture round. MPM Capital led and was joined by fellow current backers Arch Venture Partners, Oxford Bioscience Partners, Omega Fund, and Physic Ventures. A representative from MPM will take a seat on the company's board. Concurrent with the financing, Elixir announced it had granted Novartis an option to buy the company for around $500mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies